Posted by Michael Wonder on 02 Sep 2020
Talazoparib in breast cancer: hint of considerable added benefit
1 September 2020 - Advantages in health related quality of life, symptoms and side effects outweigh disadvantages.
Talazoparib is a PARP inhibitor, a pharmacological class that also includes olaparib and rucaparib, that was approved this year for the treatment of patients with breast cancer.
The IQWiG has examined in an early benefit assessment whether talazoparib offers an added benefit for these patients in comparison with the appropriate comparator therapy. Its conclusion: there is a hint of considerable added benefit. However, important data about the wellbeing of the patients after progression are missing.
